Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum cell-free supernatant
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum cell-free supernatant (CFS) is a postbiotic preparation containing the bioactive metabolites and signaling molecules secreted by the probiotic bacterium Bifidobacterium longum during its growth phase, with the bacterial cells removed. In preclinical research, specifically involving colorectal cancer (CRC) organoid models, B. longum CFS has demonstrated significant anti-tumor activity by inhibiting cancer cell growth. The therapeutic potential of this supernatant lies in its ability to deliver microbiome-derived metabolites that are often depleted in CRC patients. These metabolites are thought to modulate host inflammatory responses, immunity, and metabolic pathways to suppress tumorigenesis and progression.
- Other names
- B. longum CFSBifidobacterium longum culture supernatantBifidobacterium longum-derived metabolites
Beyond the preview
Go deeper on bifidobacterium longum cell-free supernatant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum cell-free supernatant.